No overall survival benefit from continuous as compared with fixed-duration maintenance therapy with lenalidomide in patients with newly diagnosed multiple myeloma

 Results from ENDURANCE, a randomized open-label phase III trial to determine duration of maintenance therapy in patients with newly diagnosed myeloma, has shown that "indefinite-duration maintenance with lenalidomide did not appear to have an overall survival benefit...compared to fixed-duration maintenance therapy for 2 years after induction therapy."  Further, progression-free survival after 7 years was 36.1% for the indefinite-duration group compared to 29.7% in the fixed-duration group. 

Click here to read more about the ENDURANCE study 

Sources mentioned: 

• Kumar S, Jacobus S, Cohen, A, et al. Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma . N Engl J Med 2026;395(3):221-232.
• Mian H, Costa LJ. Time to Stop? Rethinking the Duration of Maintenance Treatment in Multiple Myeloma . N Engl J Med 2026;395(3):302-303.